SCHEMBL13050153

SCHEMBL13050153

[C-]#[N+]c1ccc2c(c1)[C@@H](n1oc3cc(Cl)ccc3c1=O)[C@H](O)C(C)(C)O2

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ ABCC9 O60706 19/20 0.73
▸ KCNE1 P15382 1/20 0.39
▸ KCNQ1 P51787 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL482334 0.85 ABCC9 (1.00) ABCC9KCNE1KCNQ1
SCHEMBL482223 0.82 ABCC9 (1.00) ABCC9
SCHEMBL481830 0.82 ABCC9 (1.00) ABCC9KCNE1KCNQ1
SCHEMBL13050207 0.80 ABCC9 (1.00) ABCC9
SCHEMBL13050150 0.80 ABCC9 (0.52) ABCC9
SCHEMBL10268765 0.79 ABCC9 (1.00) ABCC9KCNE1KCNQ1
SCHEMBL13050213 0.78 ABCC9 (0.69) ABCC9KCNE1KCNQ1
SCHEMBL3442654 0.77 ABCC9 (1.00) ABCC9KCNE1KCNQ1
SCHEMBL14561901 0.77 ABCC9 (0.71) ABCC9KCNE1KCNQ1
SCHEMBL13050202 0.77 ABCC9 (1.00) ABCC9KCNE1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838553-B2 Benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2010-11-23 — — US disclosed
US-7812183-B2 Benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2010-10-12 — — US disclosed
US-20070072832-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-29 — — US disclosed
US-20070049556-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049556-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS KCNJ2, KCNN1, KCNN3 ABCC9 217/4885KCNE1 33/4885KCNQ1 15/4885
US-20070072832-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS KCNJ2, KCNN1, KCNN3 ABCC9 217/4885KCNE1 33/4885KCNQ1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback